Supernus Pharmaceuticals Inc. (SUPN) announced the results from the interim analysis from the Phase III clinical trial of SPN-810 after the close Monday. The company has decided to drop the lower dose of 18 mg. Both trials will continue through to completion at the 36 mg dose.
from RTT - Before the Bell http://ift.tt/2w6EsXb
via IFTTT
No comments:
Post a Comment